This week the headline appeared to have some tough news for RNA companies, but Alnylam remains undeterred about the potential of its treatments.» Read More
I had planned to blog about the nearly unanimous bearish analyst commentary this morning after Genentech's earnings report yesterday. The biotech giant beat on earnings per share, but came up short on Street expectations for sales of its top four drugs. DNA shares are under pressure again today.
Stocks closed sharply higher after IBM's improved outlook kicked off a market rally.
The highly anticipated results of the study that goes by the acronym "ENHANCE" are out this morning. You can see what it stands for in the companies' press release. (I wonder how many meetings and brainstorming sessions go into coming up with some of the industry's clinical trial acronyms and abbreviations.)
Merck and Schering-Plough said a closely watched study involving its Vytorin cholesterol treatment failed to reach its main goal.
Time to sort through the Fast Money inbox and answer more of your questions. Gordon writes, “Is 1390 on the S&P low enough to move the next support level - having passed through the 1400 double bottom?”
Stocks skidded back into correction territory as investors worried that the tumbling economy may not only cripple mortgage lenders like Countrywide Financial but create problems for other companies like AT&T.
The financial sector is expected to weigh on corporate earnings in the fourth quarter. But outside the sector, the news is upbeat.
After beating their own benchmark index for the last five years, Standard & Poor’s equity research team is betting on the biggest U.S. jam maker and the Magic Kingdom, among 40 companies in this year’s PowerPicks stock portfolio, to outperform again in 2008.
A contrarian investment strategy known as "Dogs of the Dow" has been a laggard this year, pulled down by Citigroup, one of the biggest casualties of the subprime credit meltdown.
The seven biggest stories in my sectors in 2007? Avandia, Dendreon, Pfizer, Biogen were just a few of the topics that made this a fascinating year for the pharmaceuticals and biotechnology industries.
Strong gains in consumer spending and technology stocks fueled a long-awaited Santa Claus rally on Wall Street.
Shares of biotech behemoth Amgen are trading at a new intra-day low in the early going this morning after the company announced new data on its developmental osteoporosis drug late Friday. The Phase 3, or late-stage, study was designed to see if the twice-a-year injectable drug strengthened the bones of women with a certain type of breast cancer.
The morning after the Merck annual business briefing, the analyst reviews are pouring in. For the most part, the ones that I've received at least, say it had a good beat. Only Sanford C. Bernstein's Tim Anderson says he can't dance to it. He titles a research note to clients, "Annual Business Review Uneventful--No Real Surprises, Positive Or Negative."
Today's Fed decision just made recession more likely, Cramer says.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
I'm back at Merck HQ in central Jersey for the annual analyst meeting. And I must say that the reception--so far, at least--is much more hospitable and helpful than last year wen things were tense and got a little ugly. A new pr team is in place.
Merck Tuesday reaffirmed its earnings forecast and said it plans to begin late-stage trials next year on a drug to raise "good" HDL cholesterol that has not been dogged by the problems that sank a similar high-profile drug being developed by Pfizer.
How aggressive will the Fed be? They are expected to cut 25 basis points and many are expecting a 50 basis point cut in the discount rate. Some are also expecting new innovations to encourage banks to use the discount window.
Earlier this week I blogged about Amgen's negative test results for its anemia drug Aranesp in breast cancer. The studies showed the drug may have caused tumors to grow and death. This morning it almost seems like there's a delayed market reaction.
I don't know how they all got clustered together--maybe so many of the major pharmaceutical companies meet with Wall Street in early December so everyone can then take off on long vacations--but my hands are full with three big pharma events in as many days. Yesterday, Merck put out guidance.
Merck gave profit forecasts for 2007 and 2008 that were mostly below expectations.